BORTEMIB works by inhibiting proteasomes in cancer cells, leading to apoptosis and tumour control.
Recommended for:
Patients with multiple myeloma (newly diagnosed or relapsed)
Patients with mantle cell lymphoma
Used in monotherapy or in combination protocols
Multiple myeloma
Mantle cell lymphoma
Administered intravenously or subcutaneously in a clinical setting. Dosage and treatment schedules vary and are determined by the treating physician.
Contraindications:
Hypersensitivity to bortezomib or excipients
Severe hepatic impairment
Pregnancy and breastfeeding
Paediatric use
Side Effects:
Nausea, vomiting, diarrhoea
Anaemia, thrombocytopenia
Neuropathy
Fatigue, dizziness
Infections
Injection site reactions